Wegovy usage in Manitoba continues to surge, with over 88,000 claims for treatments like Wegovy in the province just between 2024 and 2025
ED Relevant Adverse Effects As use continues to expand, the same physiologic effects that drive the benefits of GLP-1 receptor agonists also underlie their adverse effects and ED presentations
Since being approved by the FDA for weight loss, certain criteria need to be met to be able to receive a Semaglutide GLP-1 prescription
This combination gives providers an opportunity to connect national healthcare structures with practical support during treatment initiation and continuation
A., Sivandzade, F., Bhalerao, A
Wegovy (semaglutide): Similar to Ozempic, Wegovy contains semaglutide but is specially formulated and FDA-approved for weight management